Latest News
Izervay, a second drug to treat the advanced and severe form of dry macular degeneration known as geographic atrophy, has received full FDA approval, opening another avenue of hope for people with this vision-stealing condition.
Harnessing the power of artificial intelligence, researchers have identified nearly 200 previously unknown DNA regions linked to a risk of developing glaucoma, findings that could lead to new ways of preventing the disease.
A BrightFocus-funded team has identified a potential way to diagnose a rare but devastating form of early Alzheimer’s disease by examining cells of the inner eye.
Global nonprofit BrightFocus Foundation is pleased to announce that it has received a $50,000 donation from Alzheimer’s Los Angeles (Alzheimer’s LA) to support two innovative Alzheimer’s disease research scientists as part of the Foundation’s 2023 research portfolio.
For the first time, a research team has created laboratory-grown cone photoreceptor cells that respond to light, unlocking a potential new way to treat macular degeneration.
Research awarded by BrightFocus totals nearly $290 million to date across 25 countries, enabling innovative scientists from around the world to push the boundaries of Alzheimer’s, macular degeneration, and glaucoma research.
Donanemab, a potential new amyloid-clearing Alzheimer’s drug, has been shown to slow cognitive decline by 35% in the early stages of Alzheimer’s disease.
Blacks and Hispanics with neuropsychiatric symptoms are more likely to develop cognitive impairment, according to recent BrightFocus-funded research.
A BrightFocus-funded research team has identified how an FDA-approved antioxidant may be used to help prevent age-related macular degeneration in people with certain genetic risk factors for the disease.
The U.S. Food and Drug Administration today granted full approved of Leqembi (lecanemab-irmb) for the treatment of Alzheimer’s disease based on its ability to clear toxic amyloid from the brain.
